AMRX (Amneal Pharmaceuticals) Institutional Ownership: 56.06% (As of Jul. 11, 2026)


AMRX Amneal Pharmaceuticals Inc AMRX
56 GF Score
Price $17.01
GF Value $7.58
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Amneal Pharmaceuticals Institutional Ownership?

Amneal Pharmaceuticals AMRX -0.06% 56 Institutional Ownership is 56.06% as of Jul. 11, 2026. GuruFocus rates AMRX with a GF Score™ of 56/100 and a GF Value™ of $7.58 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Amneal Pharmaceuticals's institutional ownership is 56.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Amneal Pharmaceuticals's Insider Ownership is 2.90%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Amneal Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 67.72%.

Amneal Pharmaceuticals Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals Institutional Ownership Chart

Amneal Pharmaceuticals Historical Data

The historical data trend for Amneal Pharmaceuticals can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 22.96 22.72 23.07 23.29 29.09 29.07 29.05 28.80 29.35 29.49
AMRX
56GF Score
Amneal Pharmaceuticals Inc AMRX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amneal Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 56.06% mean?
Amneal Pharmaceuticals (AMRX) has a Institutional Ownership of 56.06% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Amneal Pharmaceuticals and its competitors.
Is Amneal Pharmaceuticals' Institutional Ownership too high?
Amneal Pharmaceuticals' current Institutional Ownership is 56.06%. Overall, Amneal Pharmaceuticals has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Amneal Pharmaceuticals' Institutional Ownership compare to INDV and KNSA?
Amneal Pharmaceuticals' Institutional Ownership of 56.06% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Amneal Pharmaceuticals and its competitors. Amneal Pharmaceuticals's current Institutional Ownership is 56.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amneal Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.58, compared to a current price of $17.01 — trading 124.4% above its estimated fair value. The current Institutional Ownership is 56.06%. Amneal Pharmaceuticals' overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current Institutional Ownership is 56.06% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.01 is trading 124.4% above its estimated GF Value™ of $7.58. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

  • Institutional Ownership: 56.06%
  • GF Value™: $7.58 vs. price of $17.01 (124.4% above fair value)
  • GF Score™: 56/100 with 6 warning signs

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Other Exchanges 2DT:Germany
Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
56GF Score

Get the complete analysis for AMRX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.01
Price
$7.58
GF Value